FOXD1 expression is associated with poor prognosis in non-small cell lung cancer

Sohei Nakayama; Kenzo Soejima; Hiroyuki Yasuda; Satoshi Yoda; Ryosuke Satomi; Shinnosuke Ikemura; Hideki Terai; Takashi Sato; Norihiro Yamaguchi; Junko Hamamoto; Daisuke Arai; Kota Ishioka; Keiko Ohgino; Katsuhiko Naoki; Tomoko Betsuyaku

FOXD1 expression is associated with poor prognosis in non-small cell lung cancer

Sohei Nakayama, Kenzo Soejima, Hiroyuki Yasuda, Satoshi Yoda, Ryosuke Satomi, Shinnosuke Ikemura, Hideki Terai, Takashi Sato, Norihiro Yamaguchi, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Katsuhiko Naoki, Tomoko Betsuyaku

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Aim: Clinical microarray datasets were analyzed to search for new therapeutic targets and prognostic markers of non-small cell lung cancer (NSCLC).

Materials and Methods: Microarray datasets from 90 lung cancer specimens, were analyzed with focus on the FOXD1 gene. Levels of FOXD1 mRNA were assessed in lung cancer cell lines and these levels were correlated with survival.

Results: FOXD1-knockdown led to suppression of cell proliferation. Moreover, patients with high FOXD1 expression survived for a significantly shorter time than those with low FOXD1 expression.

Conclusion: The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.

Original language	English
Pages (from-to)	261-268
Number of pages	8
Journal	Anticancer Research
Volume	35
Issue number	1
State	Published - 1 Jan 2015
Externally published	Yes

Keywords

FOXD1
Microarray
Non-small cell lung cancer
PTEN
Pathway signature

Cite this

@article{54973ea48ef0485cabfd79eaca711f58,

title = "FOXD1 expression is associated with poor prognosis in non-small cell lung cancer",

abstract = "Aim: Clinical microarray datasets were analyzed to search for new therapeutic targets and prognostic markers of non-small cell lung cancer (NSCLC).Materials and Methods: Microarray datasets from 90 lung cancer specimens, were analyzed with focus on the FOXD1 gene. Levels of FOXD1 mRNA were assessed in lung cancer cell lines and these levels were correlated with survival.Results: FOXD1-knockdown led to suppression of cell proliferation. Moreover, patients with high FOXD1 expression survived for a significantly shorter time than those with low FOXD1 expression.Conclusion: The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.",

keywords = "FOXD1, Microarray, Non-small cell lung cancer, PTEN, Pathway signature",

author = "Sohei Nakayama and Kenzo Soejima and Hiroyuki Yasuda and Satoshi Yoda and Ryosuke Satomi and Shinnosuke Ikemura and Hideki Terai and Takashi Sato and Norihiro Yamaguchi and Junko Hamamoto and Daisuke Arai and Kota Ishioka and Keiko Ohgino and Katsuhiko Naoki and Tomoko Betsuyaku",

year = "2015",

month = jan,

day = "1",

language = "English",

volume = "35",

pages = "261--268",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "1",

}

TY - JOUR

T1 - FOXD1 expression is associated with poor prognosis in non-small cell lung cancer

AU - Nakayama, Sohei

AU - Soejima, Kenzo

AU - Yasuda, Hiroyuki

AU - Yoda, Satoshi

AU - Satomi, Ryosuke

AU - Ikemura, Shinnosuke

AU - Terai, Hideki

AU - Sato, Takashi

AU - Yamaguchi, Norihiro

AU - Hamamoto, Junko

AU - Arai, Daisuke

AU - Ishioka, Kota

AU - Ohgino, Keiko

AU - Naoki, Katsuhiko

AU - Betsuyaku, Tomoko

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Aim: Clinical microarray datasets were analyzed to search for new therapeutic targets and prognostic markers of non-small cell lung cancer (NSCLC).Materials and Methods: Microarray datasets from 90 lung cancer specimens, were analyzed with focus on the FOXD1 gene. Levels of FOXD1 mRNA were assessed in lung cancer cell lines and these levels were correlated with survival.Results: FOXD1-knockdown led to suppression of cell proliferation. Moreover, patients with high FOXD1 expression survived for a significantly shorter time than those with low FOXD1 expression.Conclusion: The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.

AB - Aim: Clinical microarray datasets were analyzed to search for new therapeutic targets and prognostic markers of non-small cell lung cancer (NSCLC).Materials and Methods: Microarray datasets from 90 lung cancer specimens, were analyzed with focus on the FOXD1 gene. Levels of FOXD1 mRNA were assessed in lung cancer cell lines and these levels were correlated with survival.Results: FOXD1-knockdown led to suppression of cell proliferation. Moreover, patients with high FOXD1 expression survived for a significantly shorter time than those with low FOXD1 expression.Conclusion: The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.

KW - FOXD1

KW - Microarray

KW - Non-small cell lung cancer

KW - PTEN

KW - Pathway signature

UR - http://www.scopus.com/inward/record.url?scp=84920424293&partnerID=8YFLogxK

M3 - Article

C2 - 25550559

AN - SCOPUS:84920424293

SN - 0250-7005

VL - 35

SP - 261

EP - 268

JO - Anticancer Research

JF - Anticancer Research

IS - 1

ER -

FOXD1 expression is associated with poor prognosis in non-small cell lung cancer

Abstract

Keywords

Fingerprint

Cite this